Positive Phase III for IBI 10090 (dexamethasone extended release) in Cataract surgery-Icon Bioscience

Icon Bioscience has reported data from its pivotal Phase III clinical trial for IBI 10090 (dexamethasone extended release) in Cataract Surgery. The results of the trial showed that IBI 10090 is highly effective in treating inflammation post cataract surgery. In this trial, IBI 10090 showed unprecedented efficacy in reducing inflammation associated with cataract surgery, with a safety profile similar to that of placebo. It could prove to be an important new therapy as an alternative to frequent corticosteroid drop instillation in post cataract surgical care.

IBI 10090 employs Icon�s Verisome technology to dispense an extended-release, biodegradable formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single administration immediately following cataract surgery. IBI 10090 has been developed to increase efficacy by placing the drug at the site of action and to help patients, in a largely elderly population, avoid noncompliance and dosing errors associated with the comparatively burdensome process of multiple, self-administered, daily eye drops.